c-Met expression has been linked to poor prognosis in different solid tumors [3,4,5], and the overactivation of the HGF/c-Met axis has been shown to promote tumorigenesis and tumor progression in various cancer types, such as gastroesophageal adenocarcinoma, cholangiocarcinoma, colon cancer, kidney cancer, glioblastoma, melanoma, and lung cancer [6,7,8,9,10,11,12,13,14]. This evidence concerns the gene MET and kidney cancer.